Market: NASD |
Currency: USD
Address: 26 Ben-Gurion St.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
📈 XTL Biopharmaceuticals Ltd. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2017 |
- |
$0.200000 |
- |
2017-02-10 |
- |
Stock split |
|
Total Amount for 2017: $0.200000 |
📅 Earnings & EPS History for XTL Biopharmaceuticals Ltd.
| Date | Reported EPS |
|---|
| 2016-06-01 | -0.01 |
| 2016-03-31 | -0.01 |
| 2015-12-01 | - |
| 2015-09-01 | - |
| 2015-06-01 | -0.01 |
📰 Related News & Research
No related articles found for "xtl biopharmaceuticals".
